𝔼́𝕝𝕚𝕥𝕖𝕣𝕒 𝕄𝕒𝕤𝕥𝕖𝕣𝕪 𝕀𝕟𝕤𝕥𝕚𝕥𝕦𝕥𝕖
𝐸𝑚𝑝𝑜𝑤𝑒𝑟𝑖𝑛𝑔 𝐻𝑒𝑎𝑙𝑡ℎ,𝐴𝑑𝑣𝑎𝑛𝑐𝑖𝑛𝑔 𝐾𝑛𝑜𝑤𝑙𝑒𝑑𝑔𝑒
𝐸𝑚𝑝𝑜𝑤𝑒𝑟𝑖𝑛𝑔 𝐻𝑒𝑎𝑙𝑡ℎ,𝐴𝑑𝑣𝑎𝑛𝑐𝑖𝑛𝑔 𝐾𝑛𝑜𝑤𝑙𝑒𝑑𝑔𝑒
At Élitera, we set the standard for precision-engineered medical and aesthetic technology, crafted in Europe with an unwavering commitment to quality over quantity. Each device is custom-tailored to seamlessly integrate into your practice, delivering superior performance, safety, and patient satisfaction.
Our state-of-the-art solutions are designed to elevate a wide range of medical and aesthetic treatments, including:
At Élitera, we go beyond supplying equipment by offering a comprehensive support system that empowers your practice:
This is more than technology—it’s a strategic advantage. Elevate your practice with cutting-edge innovation, expert guidance, and a vision for the future.
Élitera – Precision, Performance, Perfection.
𝚁𝚎𝚟𝚘𝚕𝚞𝚝𝚒𝚘𝚗𝚒𝚣𝚎 𝙲𝚊𝚛𝚎 𝚠𝚒𝚝𝚑 𝙰𝙸-𝙳𝚛𝚒𝚟𝚎𝚗 𝙼𝚎𝚍𝚒𝚌𝚊𝚕 𝙴𝚚𝚞𝚒𝚙𝚖𝚎𝚗𝚝
Our state-of-the-art device utilizes the latest technology in the field to target and combat common signs of aging such as wrinkles, fine lines, sagging skin, and more. With customizable treatment options, you can tailor each session to meet the specific needs and goals of your clients, ensuring optimal results every time.
By incorporating our medical anti-aging device into your practice, you can offer your clients a non-invasive and effective solution to rejuvenate their skin and turn back the clock on aging. Watch as your clients leave your office feeling more confident and empowered with their youthful, radiant appearance restored.
𝐏𝐫𝐞𝐬𝐞𝐧𝐭𝐢𝐧𝐠 𝐨𝐮𝐫 𝐬𝐭𝐚𝐭𝐞-𝐨𝐟-𝐭𝐡𝐞-𝐚𝐫𝐭 𝐦𝐞𝐝𝐢𝐜𝐚𝐥 𝐝𝐞𝐯𝐢𝐜𝐞, 𝐞𝐧𝐠𝐢𝐧𝐞𝐞𝐫𝐞𝐝 𝐭𝐨 𝐞𝐧𝐡𝐚𝐧𝐜𝐞 𝐲𝐨𝐮𝐫 𝐩𝐫𝐚𝐜𝐭𝐢𝐜𝐞 𝐛𝐲 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐢𝐧𝐠 𝐞𝐱𝐜𝐞𝐩𝐭𝐢𝐨𝐧𝐚𝐥 𝐫𝐞𝐬𝐮𝐥𝐭𝐬 𝐰𝐡𝐢𝐥𝐞 𝐞𝐧𝐡𝐚𝐧𝐜𝐢𝐧𝐠 𝐲𝐨𝐮𝐫 𝐜𝐥𝐢𝐞𝐧𝐭𝐬’ 𝐜𝐨𝐧𝐟𝐢𝐝𝐞𝐧𝐜𝐞 𝐚𝐧𝐝 𝐬𝐞𝐥𝐟-𝐚𝐬𝐬𝐮𝐫𝐚𝐧𝐜𝐞.
𝐸𝑛ℎ𝑎𝑛𝑐𝑒 𝑦𝑜𝑢𝑟 𝑐𝑙𝑖𝑒𝑛𝑡𝑠 𝑠𝑎𝑡𝑖𝑠𝑓𝑎𝑐𝑡𝑖𝑜𝑛, 𝑎𝑛𝑑 𝑢𝑛𝑙𝑜𝑐𝑘 𝑎 𝑛𝑒𝑤 𝑟𝑒𝑎𝑙𝑚 𝑜𝑓 𝑝𝑜𝑠𝑠𝑖𝑏𝑖𝑙𝑖𝑡𝑖𝑒𝑠 𝑖𝑛 𝑎𝑛𝑡𝑖-𝑎𝑔𝑖𝑛𝑔 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡𝑠.
𝑊𝑖𝑡ℎ 𝑓𝑢𝑙𝑙𝑦 𝑐𝑢𝑠𝑡𝑜𝑚𝑖𝑧𝑎𝑏𝑙𝑒 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑜𝑝𝑡𝑖𝑜𝑛𝑠, 𝑦𝑜𝑢 𝑐𝑎𝑛 𝑝𝑟𝑒𝑐𝑖𝑠𝑒𝑙𝑦 𝑎𝑑𝑎𝑝𝑡 𝑒𝑎𝑐ℎ 𝑠𝑒𝑠𝑠𝑖𝑜𝑛 𝑡𝑜 𝑎𝑙𝑖𝑔𝑛 𝑤𝑖𝑡ℎ 𝑦𝑜𝑢𝑟 𝑐𝑙𝑖𝑒𝑛𝑡𝑠' 𝑢𝑛𝑖𝑞𝑢𝑒 𝑛𝑒𝑒𝑑𝑠 𝑎𝑛𝑑 𝑎𝑒𝑠𝑡ℎ𝑒𝑡𝑖𝑐 𝑜𝑏𝑗𝑒𝑐𝑡𝑖𝑣𝑒𝑠, 𝑒𝑛𝑠𝑢𝑟𝑖𝑛𝑔 𝑒𝑥𝑐𝑒𝑝𝑡𝑖𝑜𝑛𝑎𝑙 𝑟𝑒𝑠𝑢𝑙𝑡𝑠 𝑤𝑖𝑡ℎ 𝑒𝑣𝑒𝑟𝑦 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡.
Hyperbaric oxygen therapy (HBOT) is a proven modality in modern medicine, offering significant therapeutic benefits across a wide range of clinical applications. Among the available pressure options, the 2 ATA hyperbaric chamber is a critical tool for medical professionals seeking to enhance patient outcomes through improved oxygenation and accelerated healing. This article provides a comprehensive overview of the 2 ATA chamber and its relevance in medical practice.
Understanding the 2 ATA Hyperbaric Chamber
A 2 ATA (atmospheres absolute) hyperbaric chamber operates at twice the atmospheric pressure at sea level, creating an environment that dramatically increases oxygen delivery to tissues. At this pressure, oxygen is dissolved into the plasma, interstitial fluid, and cerebrospinal fluid, enabling it to reach areas with compromised circulation or high metabolic demand. This enhanced oxygen availability forms the basis for the wide range of clinical applications of HBOT at 2 ATA.
Mechanism of Action in a 2 ATA Hyperbaric Chamber
At 2 ATA, oxygen dissolves into bodily fluids at a rate significantly higher than under normobaric conditions. This process leads to:
1. Enhanced Tissue Oxygenation: Facilitates oxygen delivery to ischemic or hypoxic tissues.
2. Angiogenesis: Stimulates new blood vessel growth, improving long-term tissue perfusion.
3. Reduction of Inflammation and Edema: Reduces pro-inflammatory cytokines and facilitates lymphatic drainage.
4. Antimicrobial Effects: Enhances the bactericidal and bacteriostatic effects of oxygen, particularly against anaerobic bacteria.
Clinical Applications of 2 ATA Hyperbaric Chambers
1. Wound Healing and Chronic Ulcers
• Indications: Diabetic foot ulcers, venous stasis ulcers, and post-surgical wound dehiscence.
• Mechanism: Enhanced oxygen delivery improves fibroblast proliferation, collagen synthesis, and angiogenesis, accelerating wound closure.
2. Neurological Conditions
• Indications: Traumatic brain injury (TBI), stroke, anoxic brain injury, and post-concussion syndrome.
• Mechanism: Increased oxygenation promotes neuroplasticity and reduces inflammation in neural tissues, aiding recovery.
3. Post-Surgical Recovery
• Indications: Recovery from orthopedic, plastic, and reconstructive surgeries.
• Mechanism: Reduced swelling and enhanced tissue repair improve recovery timelines and outcomes.
4. Radiation-Induced Tissue Damage
• Indications: Osteoradionecrosis, soft tissue radionecrosis, and delayed radiation injuries.
• Mechanism: Revascularization of hypoxic tissue mitigates the long-term effects of radiation.
5. Infection Management
• Indications: Necrotizing fasciitis, chronic osteomyelitis, and gas gangrene.
• Mechanism: Synergistic with antibiotics, HBOT enhances oxygen-dependent killing of anaerobic bacteria and disrupts biofilms.
6. Adjunctive Care in Oncology
• Indications: Supportive care for patients undergoing chemotherapy or radiation therapy.
• Mechanism: HBOT reduces treatment-associated side effects, such as mucositis and tissue necrosis, while supporting overall recovery.
7. Pain and Inflammatory Disorders
• Indications: Complex regional pain syndrome (CRPS), fibromyalgia, and chronic inflammatory conditions.
• Mechanism: Modulation of inflammatory pathways and reduced oxidative stress alleviate symptoms.
Advantages of a 2 ATA Hyperbaric Chamber in Clinical Practice
1. Optimized Therapeutic Pressure
• The 2 ATA level is recognized as a clinically effective pressure for a variety of medical conditions, balancing increased oxygen delivery with patient safety.
2. Versatility Across Specialties
• A 2 ATA chamber is suitable for diverse medical fields, including wound care, neurology, oncology, and sports medicine.
3. Objective Tracking of Patient Progress
• Regular sessions at 2 ATA allow for measurable improvements in tissue oxygenation, inflammation reduction, and functional recovery, enabling physicians to monitor and document patient outcomes effectively.
4. Integration into Multimodal Treatment Plans
• As a complementary therapy, HBOT at 2 ATA enhances the efficacy of surgical interventions, pharmaceutical regimens, and rehabilitation programs.
Considerations for Medical Professionals
1. Patient Selection
• Ideal candidates include those with conditions involving hypoxia, ischemia, or chronic inflammation. However, HBOT is contraindicated in patients with untreated pneumothorax or certain pulmonary disorders.
2. Safety and Monitoring
• HBOT at 2 ATA is generally well-tolerated, but side effects such as barotrauma, oxygen toxicity, or middle ear discomfort may occur. Close monitoring during treatment is essential.
3. Reimbursement and Compliance
• Many insurance providers cover HBOT for FDA-approved indications. Ensure that your treatment protocols align with regulatory guidelines to maximize reimbursement opportunities.
Conclusion
The 2 ATA hyperbaric chamber represents a powerful therapeutic tool for medical professionals, offering a non-invasive approach to treating complex and chronic conditions. Its ability to enhance tissue oxygenation, accelerate healing, and reduce inflammation makes it an indispensable asset in modern medical practice. By integrating 2 ATA HBOT into your clinical offerings, you can improve patient outcomes, expand your practice’s capabilities, and stay at the forefront of evidence-based medicine.
Explore the benefits of a 2 ATA hyperbaric chamber and elevate your standard of care.
Botox injections may do more than erase the signs of age, or prevent you from feeling painful migraines — they may alleviate depression as well, a new study confirms.
Doctors inject Botox to smooth facial wrinkles and treat health problems such as severe sweating, uncontrollable blinking, chronic migraines, overactive bladders and neurological disorders that cause muscle contractions and pain in the neck and shoulders.
Botox, a drug made from a toxin produced by the bacterium Clostridium botulinum, works by weakening or paralyzing specific muscles or by blocking certain nerves.
Researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego have mined the U.S. Food and Drug Administration (FDA)’s Adverse Effect Reporting System (FAERS) database to see what nearly 40,000 people reported happened to them after treatment with Botox for a variety of reasons.
In the study, published July 30, 2020 in Scientific Reports, the team discovered that people who received Botox injections — at six different sites, not just in the forehead — reported depression significantly less often than patients undergoing different treatments for the same conditions.
“For years, clinicians have observed that Botox injected for cosmetic reasons seems to ease depression for their patients,” said Ruben Abagyan, PhD, professor of pharmacy. “It’s been thought that easing severe frown lines in forehead region disrupts a feedback loop that reinforces negative emotions. But we’ve found here that the mechanism may be more complex, because it doesn’t really matter where the Botox is injected.”
Abagyan led the study with Tigran Makunts, PharmD, who was a pharmacy student at the time and is now a research fellow at the FDA, and Marc Axel Wollmer, MD, a psychiatrist and researcher in Germany who has led past clinical studies in which Botox was found to alleviate depression.
The FAERS database contains more than 13 million voluntary reports of adverse effects people experienced while taking a medication. Abagyan and team have found they can also use the database to look at absence of a health complaint when a person takes a medication, if compared to a control group. In this case, they searched for the absence of depression.
The team focused on nearly 40,000 FAERS reports of people experiencing adverse events after Botox treatment. The reports cover Botox treatment for eight different reasons and injection sites, including forehead, neck, limbs and bladder. Then the team applied a mathematical algorithm to look for statistically significant differences between Botox users and patients who received different treatments for the same conditions.
Here’s what they found: Depression was reported 40 to 88 percent less often by Botox-treated patients for six of the eight conditions and injection sites.
“This finding is exciting because it supports a new treatment to affect mood and fight depression, one of the common and dangerous mental illnesses — and it’s based on a very large body of statistical data, rather than limited-scale observations,” Makunts said.
To be clear, the data used in this study was not collected for the purpose of exploring the association between Botox use and depression exclusively. In addition, the FAERS data represents only the subset of Botox users who experienced negative side effects. While the team excluded reports in which a person was also taking antidepressants, the use of other prescription and over-the-counter medications could have been underreported in some cases.
The clinical trial underway are directly testing Botox treatment for people with depression, a gold standard approach for gathering insights on the relationship between a medication and a health condition. Since that trial is only testing forehead injection of Botox, Abagyan says additional clinical trials may be necessary to work out the best site and dose to administer the medication specifically for the treatment of depression.
Likewise, more research is needed to determine the mechanism by which Botox acts as an antidepressant, Abagyan says. He and collaborators hypothesize a few possibilities worth investigating: Botox could be transported to the regions of the central nervous systems involved in mood and emotions. Or, since Botox is commonly used to treat chronic conditions that may contribute to depression, its success in relieving the underlying problem may indirectly also relieve depression.
The World Health Organization estimates that more than 264 million worldwide experience depression. Depression is frequently treated with psychotherapy, selective serotonin reuptake inhibitors, dopamine-norepinephrine reuptake inhibitors and/or serotonin-norepinephrine reuptake inhibitors. Yet these approaches are ineffective for nearly one-third of patients. That’s why clinicians and researchers are exploring other therapeutic options, including electroconvulsive therapy, transcranial magnetic stimulation, ketamine infusions and, more recently, Botox forehead injections.
The study was funded, in part, by the National Institutes of Health (grant R35-GM131881).
Disclosure: Ruben Abagyan is co-founder of Molsoft, LLC and has equity. M. Axel Wollmer has consulted for Allergan pharmaceuticals.
Send us a message
Open today | 09:00 am – 05:00 pm |
TERMS AND CONDITIONS ADDENDUM TO CUSTOMER PURCHASE AGREEMENT BETWEEN CUSTOMER AND COMPANY
Purchase Restrictions
General Ownership Conditions and System Use
Warranty Information
Elitera Mastery Institute, LLC. (“Élitera”) has agreed to provide certain services (the “Services”) to the Practice identified as Customer (“Customer”) in the Onsite Sales Event document provided to Customer by Élitera (the “Agreement”). The Agreement sets forth details of the Services Élitera will provide to Customer to assist with Customer’s launch of the Élitera device that has been purchased by Customer (the “System”). The Services are subject to the terms and conditions set forth below (the “Terms”):
Terms Applicable to Upgrade Program
The following terms (the “Upgrade Terms”) are applicable to Customer’s purchase of the Elevate System at the discounted price as part of the Company’s program allowing Customer’s to upgrade from the Vital System to the Elevate System at a reduced price (the “Upgrade Program”) as set forth in a Customer Purchase Agreement between Company and Customer. Company has sole discretion to determine whether a Customer may participate in the Upgrade Program.
𝚆𝚎 𝚞𝚜𝚎 𝚌𝚘𝚘𝚔𝚒𝚎𝚜 𝚝𝚘 𝚊𝚗𝚊𝚕𝚢𝚣𝚎 𝚠𝚎𝚋𝚜𝚒𝚝𝚎 𝚝𝚛𝚊𝚏𝚏𝚒𝚌 𝚊𝚗𝚍 𝚘𝚙𝚝𝚒𝚖𝚒𝚣𝚎 𝚢𝚘𝚞𝚛 𝚠𝚎𝚋𝚜𝚒𝚝𝚎 𝚎𝚡𝚙𝚎𝚛𝚒𝚎𝚗𝚌𝚎. 𝙱𝚢 𝚊𝚌𝚌𝚎𝚙𝚝𝚒𝚗𝚐 𝚘𝚞𝚛 𝚞𝚜𝚎 𝚘𝚏 𝚌𝚘𝚘𝚔𝚒𝚎𝚜, 𝚢𝚘𝚞𝚛 𝚍𝚊𝚝𝚊 𝚠𝚒𝚕𝚕 𝚋𝚎 𝚊𝚐𝚐𝚛𝚎𝚐𝚊𝚝𝚎𝚍 𝚠𝚒𝚝𝚑 𝚊𝚕𝚕 𝚘𝚝𝚑𝚎𝚛 𝚞𝚜𝚎𝚛 𝚍𝚊𝚝𝚊.